PRECIGEN, INC. Deferred Tax Liabilities, Leasing Arrangements
PRECIGEN, INC. (PGEN) had Deferred Tax Liabilities, Leasing Arrangements of $1.12 million as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2026-03-25
- 2025-12-31: Deferred Tax Liabilities, Leasing Arrangements $1.12M.
- 2024-12-31: Deferred Tax Liabilities, Leasing Arrangements $1.27M.
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $1.83M.
- 2022-12-31: Deferred Tax Liabilities, Leasing Arrangements $2.07M.
| Period end | Deferred Tax Liabilities, Leasing Arrangements |
|---|---|
| 2025-12-31 | $1.12M 10-K · filed 2026-03-25 |
| 2024-12-31 | $1.27M 10-K · filed 2026-03-25 |
| 2023-12-31 | $1.83M 10-K · filed 2025-03-19 |
| 2022-12-31 | $2.07M 10-K · filed 2024-03-19 |
| 2021-12-31 | $2.73M 10-K · filed 2023-03-06 |
| 2020-12-31 | $5.01M 10-K · filed 2022-03-01 |
| 2019-12-31 | $8.09M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |